Glucagon-like peptide-1 (GLP-1) receptor agonists have driven a major shift in managing diabetes mellitus (DM). Long-acting GLP-1 receptor agonists control glycemia better than short-acting agents and even better than insulin. These agents show cardioprotective and renoprotective effects and do not lead to weight gain or hypoglycemia. However, there are some dose-dependent adverse effects witnessed in clinical trials.
Analyzing the evidence regarding the benefits and adverse effects of GLP-1 receptor agonists can help guide clinicians involved in delivering care to DM patients. Join Dr. Supratik Bhattacharyya , an expert endocrinologist, in an exclusive MasterSeries session on “ GLP-1 Agonists in DM management: Comparative Analysis ” on 23 rd November 2022, 3:00 PM IST onwards. Stay tuned for the session!
